Q1 Earnings Estimate for Affimed Issued By Leerink Partnrs

Affimed (NASDAQ:AFMD) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Affimed in a report issued on Tuesday, December 17th. Leerink Partnrs analyst D. Graybosch forecasts that the biopharmaceutical company will earn ($0.59) per share for the quarter. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share.

AFMD has been the topic of a number of other reports. Wells Fargo & Company cut their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Stifel Nicolaus cut their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Affimed in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Trading Down 6.3 %

Shares of AFMD opened at $1.18 on Friday. Affimed has a 1 year low of $1.15 and a 1 year high of $8.95. The stock’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $4.10. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AFMD. Point72 Asset Management L.P. increased its position in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Jane Street Group LLC acquired a new position in Affimed in the 3rd quarter worth $44,000. Intellectus Partners LLC increased its holdings in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares in the last quarter. Choreo LLC acquired a new stake in shares of Affimed in the 2nd quarter valued at about $54,000. Finally, FMR LLC lifted its holdings in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.